FDA Approves Dupixent for Chronic Obstructive Pulmonary Disease
By Lori Solomon HealthDay Reporter
TUESDAY, Oct. 1, 2024 -- The U.S. Food and Drug Administration has approved Dupixent (dupilumab) as an add-on maintenance treatment for adults with inadequately controlled chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype.
The approval was based on results from two pivotal phase 3 trials (BOREAS and NOTUS) that evaluated Dupixent (468 and 470 participants, respectively) compared to placebo (471 and 465 participants, respectively) in adults currently on maximal standard-of-care inhaled therapy (nearly all on triple therapy) with inadequately controlled COPD and blood eosinophils ≥300 cells per μL.
Dupixent was associated with a 30 and 34 percent reduction in the annualized rate of moderate or severe COPD exacerbations over 52 weeks (the primary end point) versus placebo. Greater improvements in postbronchodilator forced expiratory volume in the first second from baseline at week 12 were also seen with Dupixent (74 mL and 68 mL versus placebo) and were sustained at 52 weeks. Safety results were generally consistent with the known safety profile of Dupixent. Cholecystitis was seen in 0.6 percent of patients on Dupixent versus 0.1 percent of patients on placebo.
"This latest FDA approval for Dupixent represents new hope for the hundreds of thousands of COPD patients in the United States who can sometimes struggle just to breathe during their everyday lives," George D. Yancopoulos, M.D., Ph.D., the president and chief scientific officer at Regeneron and a principal inventor of Dupixent, said in a statement. "Dupixent has a proven track record as a first-in-class medicine, providing benefit to the many patients suffering from type 2 inflammatory related diseases such as asthma and atopic dermatitis."
This approval of Dupixent was granted to Regeneron.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted October 2024
Read this next
ACP: AI Recommendations More Often Better Quality for Virtual Care Visits
MONDAY, April 7, 2025 -- Artificial intelligence (AI) recommendations are more often rated as better quality than final recommendations of physicians for virtual care visits made...
Adverse Outcomes Increased With Long-Term Inhaled Corticosteroids in COPD
FRIDAY, March 28, 2025 -- For patients with chronic obstructive pulmonary disorder (COPD), long-term inhaled corticosteroid (ICS) treatment is associated with increased rates of...
COPD Tied to Increased Risk for Death in Patients With Arthritis
THURSDAY, March 20, 2025 -- Adults with arthritis and chronic obstructive pulmonary disease (COPD) have a higher risk for mortality than individuals without COPD, according to a...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.